09:04 AM EDT, 06/27/2024 (MT Newswires) -- Natera ( NTRA ) said Thursday it is launching a phase 2 single-arm gastroesophageal cancer trial using Signatera, its tumor-informed molecular residual disease, MRD, test.

The study will evaluate the efficacy of trastuzumab deruxtecan in gastroesophageal adenocarcinoma patients in the adjuvant setting, Natera ( NTRA ) said.

The company said Signatera will be used to guide patient selection and assess the rate of molecular residual disease clearance in patients being treated for gastroesophageal cancer.

The trial, dubbed Decipher, will enroll 25 patients who tested positive for MRD after neoadjuvant chemotherapy and surgery, Natera ( NTRA ) said. These patients will receive the novel HER2-directed therapy instead of standard adjuvant chemotherapy, it added.

Natera ( NTRA ) said the primary endpoint of the study is MRD clearance.

Price: 112.20, Change: +0.81, Percent Change: +0.73